Hutchison MediPharma's VEGFR Inhibitor Fruquintinib Accepted By SFDA
This article was originally published in PharmAsia News
Executive SummaryA few months after its first independently developed anti-cancer drug, Sulfatinib, was officially accepted for fast-track approval by China's State FDA, Shanghai-based Hutchison MediPharma submitted its application for registration of its self-developed VEGFR inhibitor Fruquintinib
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.